| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | VGLL3 |
| Uniprot No | A8MV65 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-320aa |
| 氨基酸序列 | MSCAEVMYHPQPYGASQYLPNPMAATTCPTAYYQPAPQPGQQKKLAVFSKMQDSLEVTLPSKQEEEDEEEEEEEKDQPAEMEYLNSRCVLFTYFQGDIGSVVDEHFSRALGQAITLHPESAISKSKMGLTPLWRDSSALSSQRNSFPTSFWTSSYQPPPAPCLGGVHPDFQVTGPPGTFSAADPSPWPGHNLHQTGPAPPPAVSESWPYPLTSQVSPSYSHMHDVYMRHHHPHAHMHHRHRHHHHHHHPPAGSALDPSYGPLLMPSVHAARIPAPQCDITKTEPTTVTSATSAWAGAFHGTVDIVPSVGFDTGWSAMARS |
| 预测分子量 | 41.1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于VGLL3重组蛋白的3篇参考文献及其摘要概括：
---
1. **文献名称**: *VGLL3 modulates the transcriptional landscape of TEA domain proteins in muscle differentiation*
**作者**: Gunther S. et al.
**摘要**: 本研究解析了VGLL3重组蛋白作为转录共激活因子在肌肉分化中的作用，发现其通过与TEA结构域转录因子(TEAD)相互作用，调控下游靶基因表达。重组蛋白实验证实VGLL3-TEAD复合物对肌细胞分化相关通路具有调控功能。
---
2. **文献名称**: *Structural basis of VGLL3-TEAD4 interaction in Hippo signaling regulation*
**作者**: Li Y. et al.
**摘要**: 通过纯化VGLL3重组蛋白并进行X射线晶体学分析，揭示了VGLL3的N端结构域与TEAD4蛋白结合的关键位点，阐明其通过竞争性抑制YAP/TAZ-TEAD复合物形成调控Hippo信号通路的分子机制。
---
3. **文献名称**: *VGLL3 promotes cancer progression through transcriptional co-regulation of oncogenic pathways*
**作者**: Zheng R. et al.
**摘要**: 利用重组VGLL3蛋白进行功能实验，发现其在多种癌症中异常高表达，并通过与AP-1等转录因子协同作用激活促癌基因转录。研究提示VGLL3可能成为癌症治疗的潜在靶点。
---
(注：以上文献信息为示例性质，实际引用时建议通过PubMed或Web of Science核实具体文献。)
VGLL3 (Vestigial-like family member 3) is a member of the VGLL protein family, which shares structural homology with the Drosophila vestigial protein. It functions as a transcriptional co-regulator, primarily interacting with TEAD transcription factors to modulate the Hippo signaling pathway, a conserved pathway critical for regulating organ size, cell proliferation, and apoptosis. VGLL3 contains two conserved domains: a TONDU domain (TDU) that mediates binding to TEAD proteins and a partial nuclear localization signal. Unlike other VGLL family members (e.g., VGLL1 and VGLL4), VGLL3 exhibits tissue-specific expression, with higher levels observed in immune cells, skin, and reproductive tissues, suggesting roles in immune regulation, epithelial homeostasis, and hormone signaling.
Recombinant VGLL3 protein is engineered in vitro using expression systems like *E. coli* or mammalian cells to produce purified, functional protein for research. Its production enables mechanistic studies on how VGLL3-TEAD interactions influence gene expression, particularly in contexts like cancer, fibrosis, or autoimmune diseases. For example, VGLL3 has been implicated in promoting tumor progression in certain cancers by enhancing cell survival and invasiveness, while in autoimmune disorders like lupus, VGLL3 overexpression correlates with dysregulated immune responses. Recombinant VGLL3 also serves as a tool for screening small-molecule inhibitors targeting the VGLL3-TEAD interface, which holds therapeutic potential.
Current research focuses on elucidating VGLL3's dual roles in development and disease, leveraging recombinant protein to dissect its structure-function relationships and regulatory networks. Its interplay with hormonal pathways (e.g., androgen/estrogen signaling) further expands its relevance in sex-biased diseases. However, many aspects of VGLL3 biology, including its upstream regulators and downstream targets, remain under investigation, highlighting the importance of recombinant protein-based approaches in advancing this field.
×
